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Abstract
Background: Incidence, manifestations and case-fatality rate (CFR) of invasive pneumococcal disease (IPD) vary with
age and comorbidities. New vaccines, changing age distribution, prolonged survival among immunocompromised
patients and improved sepsis management have created a need for an update of basic facts to inform vaccine
recommendations.
Methods: Age, gender and comorbidities were related to manifestations and death for 2977 consecutive patients with
IPD in a Swedish region with 1.5 million inhabitants during 13 years before introduction of pneumococcal conjugate
vaccines (PCV) in the infant vaccination program. These data were related to population statistics and prevalence of
several comorbidities, and compared with two previous studies giving a total follow-up of 45 years in the same area.
Results: The annual incidence was 15/100,000 for any IPD and 1.1/100,000 for meningitis; highest among elderly
followed by children < 2 years. It was 2238/100,000 among myeloma patients, followed by chronic lymphatic leukemia,
hemodialysis and lung cancer, but not elevated among asthma patients. CFR was 10 % among all patients, varying
from 3 % below 18 years to 22 % ≥ 80 years. During 45 years, the IPD incidence increased threefold and CFR
dropped from 20 to 10 %. Meningitis incidence remained stable (1.1/100,000/year) but CFR dropped from 33
to 13 %. IPD-specific mortality decreased among children <2 years from 3.1 to 0.46/100,000/year but tripled
among those ≥65 years.
Conclusions: IPD incidence and CFR vary widely between age and risk groups and over time even without general
infant vaccination. Knowledge about specific epidemiological characteristics is important for informing and evaluating
vaccination policies.
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Background
Streptococcus pneumoniae causes a broad spectrum of
diseases from otitis media and sinusitis, to nonbactere-
mic pneumonia and, finally, to invasive pneumococcal
diseases (IPD; (bacteremic pneumonia, septicemia with
unknown focus and meningitis).
Individuals at extremes of age, and with various co-
morbidities run a higher risk of IPD [1–5]. Socioeco-
nomic factors, tobacco and alcohol abuse also influence
the incidence. Increasing numbers of patients living lon-
ger with multiple chronic diseases may change both IPD
incidence and outcome. Improved management of sepsis
may increase survival [6, 7]. Differences in incidence and
case fatality rate (CFR) between countries at comparable
socioeconomic levels [7], and between different time pe-
riods in the same country [8], might reflect an unequal
distribution, both over time and geographically, of clones
and serotypes with different virulence. However, such
differences should be interpreted with caution [9], because
of selection bias due to the impact of different blood
culturing practices. When fewer blood cultures are per-
formed the incidence seems lower, and if only severe cases
are blood cultured, CFRs appear higher.
Although a polysaccharide vaccine (PPV23) had been
available for risk groups > 2 years for almost 40 years
[10, 11], it was not until widespread vaccination of infants
with pneumococcal conjugate vaccines (PCV’s), that IPD
incidence went down [12, 13] both among vaccinated
children and unvaccinated adults in many countries.
Since then, PCV13 (Prevnar13®), has become recom-
mended, for example in the US, among immunocompro-
mized adults [14] and adults aged ≥65 years, administered
in series with PPV23 [15]. Since serotype distribution
varies geographically and over time [8], both with and
without the selective pressure of vaccination, continued
success cannot be taken for granted in a long term
perspective [16].
In Sweden, at the time of the study (1996–2008)
PPV23 was recommended for certain risk groups [17]
but largely underused. PCV was used in certain high
risk groups but had not yet been introduced in the
general childhood vaccination program. Gothenburg,
with a population of 600,000, is the second largest
city in Sweden, and capital of the Västra Götaland re-
gion with 1.5 million inhabitants. Incidence, manifes-
tations and risk factors of IPD have been studied in
the Gothenburg area in two earlier studies [5, 18] during
32 years, using the same study protocol, performed
by a part of the present research team (Birger Trollfors,
Mats Dahl).
The primary objective of this study was to investigate
incidence, risk factors, manifestations, CFR and disease
severity for all patients with IPD in the Västra Götaland
Region during 13 years before introduction of PCV in
the general childhood vaccination program, in January
2009. Secondary objectives were to compare greater
Gothenburg with smaller cities and rural areas in the re-
gion, explore long-term trends over 45 years, and to esti-
mate the relative risk for morbidity and mortality from
different IPD manifestations in different age groups and for
patients with specific comorbidities, in order to identify
those with the highest potential benefit from vaccination.
Methods
IPD was defined as an infectious episode during which
pneumococci were isolated from normally sterile body
fluids. All episodes of IPD during 1996–2008 in the
Västra Götaland region (mean population 1,512,233)
in Sweden were identified by the five microbiological
laboratories serving all hospitals in the area. Data
concerning age, sex, home municipality, manifestations,
duration of hospitalization, death and sequelae were
retrieved retrospectively from the medical records.
Demographic information concerning population by
municipality, age and sex in the region for each year
retrieved from Statistics Sweden (SCB) were used to
calculate incidence. Data on comorbidities, defined as the
presence of co-existing medical conditions known or sus-
pected to be related to an increased risk to get IPD, were
also retrieved from records (as displayed in Table 1). CD4
counts at time of IPD were known for all patients with
known HIV infection. Data on smoking was excluded
since this information was missing in >50 %.
Manifestations were defined as follows: Pneumonia or
sinusitis required verification by X-ray or autopsy.
Meningitis required isolation of pneumococci from
cerebrospinal fluid (CSF) or positive blood cultures in
combination with clinical symptoms and CSF cell
counts. Septic arthritis required isolation of pneumococci
from synovial fluid. Septicemia from an unknown focus
was diagnosed when no focal infection could be identified.
Osteomyelitis, otitis media, cellulitis and bronchitis were
diagnosed clinically. Patients with mixed clinical diagnoses
(of IPD) were handled as follows: Patients with meningitis
and another manifestation were classified as meningitis,
patients with pneumonia and some other non-meningitic
manifestation were classified as pneumonia, and the
remaining patients who neither had meningitis nor pneu-
monia were classified as described above. The remaining
patients were classified as “sepsis without a defined focus”.
CFR was defined as the proportion of patients who died
within 30 days from culture, since IPD was considered to
be a contributing factor also in patients who died from
other reasons during this time interval. Dates of death
were provided through patient records and by SCB. Mor-
tality, defined as the number of deaths due to IPD/100,000
inhabitants/year, was calculated as the function of annual
incidence and CFR.
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Disease severity was estimated by ICU stay, need for
mechanical ventilation, and complications (e. g. parapneu-
monic effusion, empyema, myocardial infarction). Epi-
sodes starting more than 168 h after admission to hospital
for another reason were defined as nosocomial. All data
for patients from the city of Gothenburg and 5 surround-
ing municipalities (population 643,620) were compared
with data from the rest of the region (smaller cities and
countryside). Long term trends concerning incidence,
CFR and mortality were explored by comparing the data
from Gothenburg with surroundings with data from two
previous studies from the exactly the same area [5, 18],
using the same study protocol, by the same principle re-
searcher (BT), giving a total follow up time of 45 years.
Table 1 Predisposing factors in 2977 patients with invasive pneumococcal disease: proportion, incidence rates and risk of death












RR to get IPD
(95 % CI)
Cardiovascular disease 720 (24) 126 18 2.35 (1.90–2.92)a
Pulmonary disease 531 (18) 51 10 0.97 (0.73–1.29)
- COPD 307 (10) 38 12 1.29 (0.94–1.78) 49,000 48 3.52 (3.12–3.98)a
- Asthma 145 (5) 4 3 0.27 (0.10–0.71)b 130,000 9 0.57 (0.48–0.68)b
Malignancy 485 (16) 87 18 2.16 (1.71–2.72)a 72,000 52 4.09 (3.69–4.52)a
- Haematological 257 (9) 35 14 1.43 (1.03–1.99)a 4900 403 29.16 (25.66–33.13)a
- - Myeloma 128 (4) 23 18 1.89 (1.28–2.78)a 440 2238 154.37 (132.51–179.84)a
- - Chronic Lymphatic Leukemia 53 (2) 4 8 0.76 (0.29–1.96) 950 429 28.86 (22.13–37.63)a
- Solid tumors 158 (5) 50 32 3.66 (2.82–4.73)a 67,200 18 1.26 (1.07–1.48)a
- - Lung 52 (2) 21 40 4.33 (3.05–6.13)a 1200 333 22.40 (17.11–29.33)a
- - Breast 23 (1) 0 0 n.a. 14,600 12 0.81 (0.53–1.22)
- - Colon 22 (1) 4 18 1.85 (0.76–4.53) 4600 37 2.44 (1.61–3.72)a
- - Prostate 46 (2) 5 11 1.10 (0.48–2.54) 11,900 30 1.99 (1.49–2.67)a
Diabetes mellitus 336 (11) 36 11 1.10 (0.79–1.52) 60,500 43 3.18 (2.83–3.57)a
Autoimmune Disease 227 (8) 26 11 1.17 (0.80–1.72)
- Rheumatoid Arthritis 80 (3) 8 10 1.01 (0.52–1.97) 8500 72 4.91 (3.93–6.14)a
- Polymyalgia rheumatica 44 (1) 7 16 1.63 (0.82–3.23)
- Systemic Lupus Erythematosus 23 (1) 2 9 0.88 (0.23–3.32) 830 213 14.19 (9.64–21.28)a
Liver disease 99 (3) 11 11 1.13 (0.64–1.99)
Renal disease 109 (4) 17 16 1.61 (1.03–2.53)a
- Haemodialysis 17 (1) 5 29 3.01 (1.43–6.34)a 385 340 22.56 (14.15–35.98)a
- Peritoneal dialysis 5 (0) 1 20 2.03 (0.35–11.75) 137 281 18.57 (7.85–43.96)a
Immune deficiency 93 (3) 7 8 0.76 (0.37–1.55)
- HIV 13 (0) 1 8 0.78 (0.12–5.13) 407 246 16.30 (9.53–27.87)a
- Bone Marrow Transplant 20 (1) 2 10 1.01 (0.27–3.79)
- Hypogammaglobulinemia 22 (1) 0 0
- MGUS 26 (1) 2 8 0.59 (0.16–2.26) 17,000 12 0.81 (0.56–1.19)
Immunosuppressive treatment 279 (9) 36 13 1.35 (0.97–1.87)
Asplenia 41 (1) 5 12 1.24 (0.54–2.84) 1500 210 14.08 (10.38–19.10)a
Alcohol Dependency 220 (7) 23 10 1.06 (0.71–1.59)
≥ 1 predisposing factore 1994 (67) 257 12.9 3.43 (2.45–4.81)a
All Episodes 2977 (100) 294 9.9 1,512,233 15
n.a not applicable
aSignificantly higher relative risk (RR) to to die respectively to get IPD within 30 days from culture for a patient with this risk factor compared to all patients
without this risk factor
bSignificantly lower RR to die respectively to get IPD among asthma patients. The risk to die remainded significantly lower after correcting for age, sex and
comorbidity. See text for details
cEstimated average no of patients living in the area based on estimated prevalence
dEstimated annual incidence among patients living with factor
eAll patients with at least one risk factor. CFR among patients without any risk factor was 3.8 % (37/983)
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In order to calculate incidence in specific risk groups,
prevalences of several comorbidities were estimated as
follows: Exact data on the number of HIV and dialysis
patients were provided by the Department of Commu-
nicable Disease Control and Prevention, Västra Götaland
Region, and the Swedish Renal Registry, respectively.
Prevalence of monoclonal gammopathy of undetermined
significance (MGUS), asplenia, rheumatoid arthritis, sys-
temic lupus erythematosus (SLE) and diabetes mellitus
was estimated based on data from prevalence studies of
these conditions [19–23]. Two patients, who developed
myeloma within two years from their IPD episode, were
classified as having MGUS since this condition has been
shown to precede myeloma [24]. Prevalence of malignant
diseases was estimated on data from 2008 provided by
The National Board of Health and Welfare (http://
www.socialstyrelsen.se/statistik/statistikdatabas/cancer).
The definition of Chronic Obstructive Pulmonary Disease
(COPD) included emphysema and chronic obstructive
bronchitis. Patients with both asthma and COPD were
categorized only as COPD. Prevalence of asthma was esti-
mated to be 8.3 % in adults (16–75 years) [25], whereas
asthma prevalence in the age groups 0–15 years and above
75 years, and COPD prevalence above 16 years was esti-
mated to be 9, 7 and 4 %, respectively, from unpublished
data (Bo Lundbäck, Gothenburg University, personal
communication). All asthma and COPD prevalence esti-
mates were based on large studies conducted in the same
area as the present study and during approximately the
same time period. We abstained from estimating IPD inci-
dence among patients with cardiovascular diseases, liver
disease and alcohol abuse due to difficulties to define
prevalence rates corresponding to our case definitions but
these conditions are included among comorbidities.
Descriptive statistics (means, annual incidence rates,
CFR and mortality rates) were calculated using Excel.
The total number of blood cultures in each laboratory
and the number of inhabitants in the region for each
year were included in a linear model, in order to assess
if there was an increasing number of blood cultures per
inhabitant during the period. Medians were compared
using Mann–Whitney U test. Relative risk and confi-
dence intervals for relative risks were calculated using
CIA version 2.1.2 [26]. All other statistical analyses were
performed using SPSS version 19.0.0. Relative risks were
calculated in univariate analyses as follows: the risk to
die among patients with a certain manifestation or pre-
disposing factor was compared to the risk to die among
patients without this manifestation or predisposing fac-
tor, and the risk to get IPD among people living with a
certain predisposing factor was compared to the risk
among all inhabitants without that factor. In order to es-
timate odds ratio (OR), a multiple logistic regression
model was constructed with death within 30 days as
outcome and asthma, age, sex and comorbidity as ex-
planatory variables. The comorbidity variable was con-
structed with respect to all predisposing factors other than
asthma. The confounders that were included in the mul-
tiple logistic regression model were selected as being
known as important from earlier studies. The number of
events (case fatality) was 294 which allowed us to include
additional variables in the multiple model (according to
criterion 10:1, events per included variable). Two-tailed
Fisher’s test was used to compare proportions.
Results
Study population
Altogether 3101 episodes of IPD were diagnosed in 1996–
2008. Of these, 121 afflicting non-permanent residents
were excluded. Complete clinical data were available in
2977 of 2980 episodes (99.9 %) afflicting 2885 permanent
residents aged 0–101 years. Only age and gender were
known for the remaining three. Mean and median ages
were 60.6 and 65 years, respectively. Altogether 1483 epi-
sodes occurred in men and 1494 in women.
Pneumococci were isolated from blood alone in 2756,
from CSF alone in 40, from blood and CSF in 111, from
another sterile site alone in 36, and from blood and
another sterile site in 34 episodes.
1. IPD incidence related to age and sex
The mean IPD incidence was 15.1/100,000
inhabitants/year. The number of blood cultures
per inhabitant per year in the region doubled
during the study period; still, yearly IPD incidence
(range 12.8–18.5) did not show any increasing nor
decreasing trend (data not shown). The annual IPD
incidence was significantly higher in all age groups
compared to the group 2–17 years old: it was
highest among people ≥65 years (45/100,000),
followed by infants 0–23 months (23/100,000) (Fig. 1).
Fig. 1 Age-specific incidence rates of invasive pneumococcal
disease in men and women in different age groups
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2. Comorbidity.
The patients suffered from one or more
comorbidities in 1994 (67 % of all) IPD episodes
(Table 1). The most common were cardiovascular
and pulmonary disease, followed by malignancies and
diabetes. Altogether 983 patients did not have any
comorbidity. Vaccination status was known in 720
patients. Only 67 were known to have been vaccinated
against pneumococci, almost all with PPV-23.
3. Manifestations
Pneumonia was the most common manifestation,
followed by septicemia with unknown focus and
meningitis (Table 2). A variety of more rare
manifestations were observed (Table 3). The
distribution of manifestations varied greatly with
age. Among infants younger than 2 years, 31 %
had meningitis compared to 5 % among elderly
≥65 years, whereas pneumonia occurred in 25 % of
infants and 79 % of elderly. The annual meningitis
incidence was 1.1/100,000. It was highest in
children 0–1 years old, 7.0/100,000, and 2.0/100,000
among people ≥65 years. The annual incidence of
non-meningitic infections was 14.1/100,000. It was
highest among people ≥ 65 years, 42.8/100,000 and
15.5/100,000 among 0–1 year old children. The
incidence of bacteremic pneumonia alone was
11.5/100,000/year.
4. Case Fatality Rate
CFR was 9.9 %. It increased with age (Fig. 1), and it
was higher in men (12 %) than in women (9 %),
p < 0.01, even though the median age was higher in
women than in men, 67 vs 64 years, p < 0.001. A
multivariate logistic regression analysis yielded that
male sex was an independent risk factor for death,
after correcting for age, comorbidity in general and
cardiovascular disease and alcohol abuse in particular
(OR = 1.5, 95 % CI (1.17–1.96)). The difference in
CFR between sexes was most pronounced between
50 and 70 years of age.
Median age of those who died was 81 (range 9–100)
years and of those who survived 55 (range 0–101)
years (p < 0.001). CFR was 12.9 and 3.8 % among
patients with and without comorbidities, respectively
(Table 1). CFR also varied with manifestation, being
highest among patients with septicemia with
unknown focus, followed by meningitis and
pneumonia (Table 2).
5. Disease severity and complications
Only 25 patients were treated as outpatients.
Altogether 76 (3 %) episodes were hospital acquired,
24 (32 %) of them died. Length of stay (LOS), known
for 2561 admissions, varied between less than one to
525 days (mean 12 days, median 7 days). In-hospital
mortality was 12 % among patients with known LOS.
Altogether 477 patients were admitted to the ICU,
128 (27 %) with meningitis and 292 (61 %) with
pneumonia. The average ICU LOS was 6.8 days
(range 0–104). Altogether 202 patients were treated
with mechanical ventilation. CFR was 18 % and
in-hospital mortality 21 % among ICU patients.
Table 2 Manifestations in 2977 children and adults with invasive pneumococcal disease: proportions, age distribution and relative
risk to die
No. (%) of all Episodes in different age groups Fatalities
Manifestationa 0–1 y. 2–17 y. 18–50 y. 51–64 y. 65–101 y. All ages Died No. CFR % RR risk of death
(95 % CI)
Septicaemia with no detectable focus 31 (32) 26 (26) 39 (7) 63 (9) 180 (12) 339 (11) 70 21 2.43 (1.91–3.10)b
Meningitis 30 (31) 16 (16) 42 (7) 47 (7) 73 (5) 208 (7) 28 13 1.40 (0.97–2.01)
- without pneumonia 30 16 38 33 52 169 23 14 1.41 (0.95–2.10)
- with concurrent pneumoniaa 0 0 4 14 21 39 5 13 1.30 (0.57–2.98)
- with concurrent acute otitis mediaa 1 2 12 10 13 38 1 3 0.26 (0.04–1.83)
Pneumonia without meningitis 24 (25) 46 (46) 478 (80) 519 (78) 1199 (79) 2266 (76) 188 8.3 0.56 (0.44–0.69)c
- with Empyema 1 2 19 19 31 72 0 0 N.A.d
- with parapneumonic effusion 0 1 24 21 58 104 6 6 0.59 (0.27–1.30)
Other manifestations without pneu. or men. 12 (12) 11 (11) 35 (6) 37 (6) 69 (5) 164 (6) 8 4.9 0.48 (0.24–0.95)c
- Other manifestation together with pneumonia or
meningitisa
3 4 31 35 42 115 3 3 0.26 (0.08–0.79)c
- all patients with other manifestations. 15 15 66 72 111 279 11 4 0.38 (0.21–0.68)c
All episodesa 97 99 594 666 1521 2977 294 9.9
aIn 147 episodes, more than one manifestation was detectable
bStatistically significant higher relative risk to die than in all episodes without this manifestation
cStatistically significant lower relative risk to die than in all episodes without this manifestation
dNot applicable
Backhaus et al. BMC Infectious Diseases  (2016) 16:367 Page 5 of 12
One or more specified complications occurred in
298 episodes. In 31 of them the patient died.
Parapneumonic effusion was the most common
(104), followed by empyema (70) and myocardial
infarction (34). Multiple organ dysfunction, acute
renal failure, adult respiratory distress syndrome,
stroke and secondary nosocomial infections
occurred in 10–20 patients each, often more than
one during the same episode. Among 180 patients
who survived meningitis, 70 (39 %) had sequelae.
Neurologic sequelae, such as paresis and/or hearing
loss dominated. Among 37 children <5 years with
meningitis, one died and sequelae developed in 10,
whereas 18/73 patients ≥65 years died and 25/73
had sequelae.
6. Geographical differences
Altogether 1083 IPD episodes occurred in
Gothenburg and 5 surrounding municipalities,
giving an annual incidence of 12.9/100,000,
compared to 1894 episodes and 16.8/100,000 in the
surrounding region (p < 0.001). CFR was 9 % (93/
1083) Gothenburg with surroundings and 11 %
(201/1894) in the region (p = 0.08). The proportion
of patients ≥80 years was lower 201/1083 in
Gothenburg compared to 426/1894 in the region
(p = 0.012). Incidence in this age group was 48 and
71/100,000/year, respectively. Age specific CFR was
identical in both areas (data not shown). The
distribution of underlying conditions was similar
except that 12 % of the patients from Gothenburg
with surroundings were known to be alcohol
dependent compared to 5 % in the region (p < 0.001).
7. Long-term trends during 45 years: comparison with
two earlier studies
Neither incidence nor CFR did show any trend
during the study period 1996–2008 (data not
shown). In contrast, annual incidence of all IPD
had increased from 5.3/100,000 to 10.3/100,000
from 1964–1980 to 1981–1995 (p < 0.01), and it
had increased further to 12.9/100,000 in 1996–2008
(p = 0.03) (Table 4). The annual meningitis
incidence remained stable, 1.1/100,000 compared to
1.3 and 1.4/100,000 earlier. Age specific incidence
among infants (<2 years) did not change
significantly, whereas annual incidence among
persons ≥65 years had increased from 11/100,000 in
1964–1980 to 30/100,000 in 1981–1995 (p < 0.001),
to 40/100,000 (p = 0.05), in the present study. The
male female ratio was 1:1, compared to 2.1:1 and
1.3:1 in 1964–1980 and 1981–95, respectively. The
proportion of patients with any underlying disease
had remained stable during 45 years (68–72 %). In
contrast, the proportion of patients with known
alcohol dependency had decreased from 27 % in
1964–1980 to 12 % in 1981–1995, whereas this
proportion remained the same in 1996–2008.
Table 3 Age distribution of other invasive pneumococcal disease manifestations in children and adults
No. of Episodes in different age groups
Other Manifestationsa 0–1 y. 2–17 y. 18–50 y. 51–64 y. 65–101 y. All ages
Upper respiratory tract infections (URTI)
- acute otitis media 6 7 18 14 18 63
- sinusitis 4b 3 18 10 5 36
- epiglottitis 0 0 3 8 4 15
- other URTI 3 3 3 4 5 18
Skin, bone, joint and soft tissue
- septic arthritis 1 1 4 12 38 56
- erysipelas, cellulitis, phlegmone, abscess 2 0 4 10 17 33
- osteitis 1 2 2 4 7 16
Intra abdominal
- peritonitis 0 0 5 6 2 13
- cholecystitis, cholangitis 0 0 0 1 6 7
- salpingitis, tubo-ovarian abscess 0 0 7 0 2 9
Endocarditis 0 0 3 7 6 16
Pericarditis 0 0 0 0 7 7
Endophtalmitis, pyelonephritis, purulent thyreoiditis 0 0 0 0 5 5
No of episodesa 15 15 66 72 111 279
aIn 19 episodes, more than one manifestation other than pneumonia or meningitis was detectable
bAll infants with sinusitis suffered from ethmoiditis
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CFR had decreased to 9 % from 15 % in 1981–95
(p < 0.001), when it had decreased from 20 % in
1964–80 (p = 0.03). During the last 13 years, 13 %
died within 24 h of culture compared to 25 % in
both previous studies. CFR among meningitis
patients was 13 %, compared to 33 % in 1964–1980.
Mortality, was significantly lower in the age groups
18–50 and 51–64 years in 1996–2008 compared to
1964–1981, whereas it had increased significantly
among patients aged 65 years and above (Table 4),
all p-values < 0.05. There was also a decreasing
tendency in the age group 0–1 years.
8. Relative risks for patients with specific comorbidities
The estimated annual IPD incidence varied widely
between specific risk groups (Table 2). It was
highest among myeloma patients, followed by
patients with chronic lymphatic leukemia,
hemodialysis, lung cancer, HIV, SLE, asplenia,
rheumatoid arthritis, COPD, and diabetes mellitus.
The CD4 count at the time of infection was known
for all HIV patients; all but one had <270 cells/μL,
and 7/13 had < 200 cells/μL. Asthma without
COPD did not lead to an increased incidence.
The risk to die within 30 days for patients with any
comorbidity was 3.4 (2.45–4.81) times higher than
for patients without. The highest relative risk to
die was seen among patients with solid tumors
(especially lung cancer), followed by patients
with hemodialysis, cardiovascular disease and
hematological malignancy, especially myeloma.
CFR was significantly lower among asthma patients
(RR = 0.27 (95 % CI 0.10–0.71) compared to all
patients without asthma. A multiple logistic
regression model considering age, sex and
comorbidities, showed that the risk to die was still
significantly lower among asthma patients compared
to IPD patients without asthma, OR = 0.35 with 95 %
CI (0.12–0.96). Only four asthma patients died; three
suffered from other comorbidities and the fourth was
90 years old.
Table 4 Incidence, case fatality rate and mortality in invasive pneumococcal disease in greater Gothenburg during 45 years
1964–1980 (17 years)
Age (years) Mean pop.a No. IPD Incidenceb Died (No.) CFR (%)c Mortalityd
0–1 15,248 52 23 8 15 3.1
2–17 118,570 32 2 3 9 0.1
18–50 264,282 161 4 28 17 0.6
51–65e 98,657 129 9 27 21 1.6
66–101e 79,387 134 11 34 25 2.5
All ages 576,143 508 5 100 20 1.0
1981–1995 (15 years)
Age (years) Mean pop.a No. IPD Incidenceb Died (No.) CFR (%)c Mortalityd
0–1 15,169 67 29 5 7 2.2
2–17 103,624 35 2 3 9 0.2
18–50 280,287 189 4 18 10 0.4
51–64 84,475 167 13 27 16 2.1
65–101 99,233 441 30 83 19 5.6
All ages 582,789 899 10 136 15 1.6
1996–2008 (13 years)
Age (years) Mean pop.a No. IPD Incidenceb Died (No.) CFR (%)c Mortalityd
0–1 11,636 37 24 1 3 0.66
2–17 118,604 31 2 1 3 0.06
18–50 308,938 257 6 9 4 0.22
51–64 102,280 228 17 10 4 0.75
65–101 102,161 530 40 72 14 5.4
All ages 643,620 1083 13 93 9 1.1
aMean population during the period. Values for 1964–1980 are calculated on data from 1968–1980
bIncidence: No. of IPD episodes/100,000 inhabitants/year
cCase fatality rate
dNo of patients who died from IPD/100,000 inhabitants/year
eData from 1964–80 concern 51–65 and 66 years and above
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9. Multiple episodes
Altogether 69 patients suffered from two episodes,
7 patients had three and two had four episodes. At
the time of the first episode their age ranged
between 1 and 89 years (mean 62 and median 68).
All of them except one suffered from at least one
comorbidity. Most common was hematologic
malignancy which was present in 30 patients, 16 of
them with myeloma. Six asplenic patients had 2–3
episodes each, all of them splenectomized because
of hematologic disease. Of 78 patients with >1
episode, 10 died.
Discussion
It is well known that the IPD incidence is highest among
the elderly and small children. Although small children suf-
fered from a substantial burden of disease in the present
study, the incidence was considerably lower than among
elderly, despite the fact that the study was performed prior
to introduction of PCV in the childhood vaccination pro-
gram. The annual incidence among children aged 0–1
years, 23/100,000, was low compared to many other coun-
tries prior to PCV vaccination, although large variations are
seen between populations at a comparable socioeconomic
level [13, 27]. The relatively low incidence in this age group
might depend on blood culturing habits, since blood cul-
tures are usually only performed in patients clinically evalu-
ated as needing antibiotics intravenously. All children in
this study were in-patients, compared to a study from the
US, showing an annual incidence of 188/100,000 among
children <2 years prior to PCV vaccination; only 29 % were
in-patients [13]. Furthermore, since the blood volume
obtained for culture often is suboptimal in children undiag-
nosed IPD might be more common among children.
A majority of all IPD episodes in this and other studies
occurred in patients with previously well-described risk
factors [3–5, 18, 28], and the CFR varied widely between
risk groups. Death was extremely rare among patients
below 45 years without any comorbidity. Because we did
not have reliable data to estimate the size of the popula-
tion without any risk factor, we calculated the relative risk
to get IPD for each risk factor compared to all other pa-
tients, which may lead to an underestimate compared to a
US study [3], that estimated the relative risk among adults
with a comorbidity compared to healthy citizens.
The distribution of manifestations varied with age. For
example only 25 % of 0–1 year old children with IPD
had pneumonia, which is similar to studies from
Switzerland and Japan [29, 30]. Notably, as many as
10 % suffered from more rare IPD manifestations, such
as septic arthritis, peritonitis, endocarditis, was also
more than previously described.
A CFR of 9.9 % is low compared with the earlier stud-
ies from the same area [3, 4, 28]. This is remarkable,
since the proportion elderly was found to be high. CFR
varied between manifestations; it was highest among pa-
tients with septicemia with unknown focus, compared to
all other manifestations, probably because a high propor-
tion of these patients had comorbidities. The CFR was
also higher among meningitis patients, as expected. Com-
plications and sequelae were also common, especially
among meningitis patients, emphasizing the need for pre-
vention through vaccination.
It is well-known that IPD epidemiology is influenced
by age distribution and socioeconomic factors, and it is
therefore not surprising that we found differences be-
tween the city of Gothenburg with suburbs and the rest
of the region, where a greater proportion live in small
towns and rural areas. The incidence in Gothenburg was
lower, which was probably attributable to the fact that
the proportion elderly ≥80 years was significantly lower
both among IPD patients and in the whole population.
However, age-specific incidence among inhabitants
≥80 years was also lower in Gothenburg compared to
the rest of the region, 48/100,000/year compared to 84/
100,000/year (p < 0.001). This might reflect that nursing
home patients were less often referred to hospital and
blood cultured in the large city than in the countryside.
Another important finding was that alcohol abuse
was more common among patients from the large
city. This could have been expected to contribute to
an increased total incidence in the Gothenburg area but
paradoxically did not.
The increase in IPD incidence during 45 years was
probably largely influenced by increased blood culturing
frequency and improved culturing techniques. However,
during the last 13 years, there was no further large in-
crease in incidence despite the fact that the number of
blood cultures per capita in the region doubled. Other
contributing factors to the increase in IPD incidence
could be increased life expectancy. In Sweden life expect-
ancy increased between 1964 and 2008 from 74 to 80 years
(www.scb.se). Survival has also increased in many serious
diseases known to predispose to IPD. Finally, different
clones within the same serotype may have different viru-
lence. A new clone of serotype 1 which mainly causes IPD
in healthy adults emerged in Sweden during the study
period [31]. The long-term decrease in CFR is probably
influenced by the increased blood culturing detecting
more uncomplicated cases, but better intensive care prob-
ably also contributes to the decrease.
Meningitis incidence, however, remained rather stable
during 45 years, with a slight decline during the last
period. The CFR in meningitis patients declined from 33
to 13 %. Since there are no low symptomatic cases of
meningitis, the incidence and CFR are less influenced by
culturing practices, and more likely to be closer to the
“true” incidence and CFR. CSF cultures are almost always
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performed, unless there are medical contraindications,
and when a lumbar puncture cannot be performed, blood
cultures usually give the diagnosis. The “true” incidence of
pneumococcal bacteremia can only be estimated by an
ideal study wherein all patients in a defined population
with any symptom that possibly could be caused by a
pneumococcal infection would be extensively blood
cultured prior to antibiotic therapy.
Notably, the male female ratio decreased from 2.1:1 to
1:1 from the sixties until present. One contributing
reason is probably a decrease in the proportion of alco-
holics, which was found to be the factor with the most un-
equal sex distribution, 11 % of men versus 4 % of women
in the present study. Smoking habits may also contribute,
since the proportion smokers decreased much more
among men than among women during the same period.
However, this gender equalization cannot solely be ex-
plained by a decline in the proportion of alcoholics and
smokers, which is underlined by the fact that it also oc-
curred among the youngest children. In contrast, CFR
remained significantly higher among men than among
women, even after correcting for age and comorbidity.
IPD mortality among children 0–23 months was much
lower in this study compared to the two earlier studies,
and much lower than in most parts of the world. Inter-
national experiences from general childhood vaccination
give hope of success [12]. However, concerns that serotype
replacement might erode the gains in a longer time scale
[13, 32–34], underline the need for reliable baseline data
before vaccination is started. Although vaccination of small
children provides some protection to unvaccinated adults
with increased risk through herd effects, this does not
replace the need for vaccination of adult risk groups.
The highest annual IPD incidence was seen among pa-
tients with multiple myeloma: 2238/100,000, which was
154 times higher than for persons without myeloma.
This was even higher than previously described [35].
PPV-23 has been shown to be poorly immunogenic in
myeloma patients [36], and it remains to be shown if
PCV is more effective. Since new treatment strategies
have led to increased survival the need to prevent IPD in
this group has increased. Recurrent infections were also
common among myeloma patients, as described previ-
ously [37]. Myeloma is always preceded by MGUS [19],
known to predispose for bacterial infections [38]. How-
ever, we were not able to show increased IPD incidence
among MGUS patients, probably because many patients
with this condition are undiagnosed. That patients with
chronic lymphatic leukemia and lung cancer had a very
high IPD incidence corresponds to previous studies [35].
The same is true for patients with renal disease, espe-
cially those with hemodialysis [4].
Only 13 of 3000 IPD episodes occurred in HIV posi-
tive patients. All of them except one had low levels of
CD4-cells. IPD incidence is known to be elevated among
HIV patients when CD4 counts are <200 cells/μL [39]. It
has declined following introduction of highly active anti-
retroviral therapy (HAART) [40]. Our findings were ex-
pected, since, at time of the study, HAART therapy was
available for free and only 0.03 % of the inhabitants in
the area were known to be HIV positive.
The estimated incidence of IPD was significantly lower
among persons with asthma compared to persons with-
out asthma. Furthermore, CFR among asthma patients
with IPD was also lower than among patients without
asthma, even when adjusting for age and comorbidities.
This finding is easily explained by the fact that very few
of the patients (54/1521) in the age group with the highest
IPD incidence and highest CFR (≥65 years), were reported
to have asthma. In the age group 2–49 years, no difference
in incidence between persons with and without asthma
was found. This finding contrasts to a study from Tennes-
see, US, where asthma was shown to be an independent
risk factor for IPD in this age group [41]. Altogether 114
(18 %) of 635 IPD cases and 516 (8.1 %) of 6350 controls
in that study had asthma. Asthma became included as an
indication for pneumococcal vaccination as a result of that
study [42]. The most probable explanation for why asthma
was a risk factor for IPD in the US but not in the present
study is differences between the study populations. The
proportion of patients with coexisting factors higher in
the American study, the American study primarily com-
prised persons of low socioeconomic status enrolled in a
Medicaid program, whereas the Swedish study is popula-
tion based. Furthermore, the asthma patients in the
American study were not on optimal supportive treat-
ment, illustrated by the fact that 8 % of IPD patients with
asthma had received long-term oral corticosteroids and
25 % had been hospitalized for asthma within the previous
year. In contrast, prevalence of respiratory symptoms was
low among Swedish asthma patients during the same
period, according to a study performed in the same area
[25]. Furthermore, different case definitions may contrib-
ute to different conclusions, since use of asthma medica-
tion was part of the case definition in the American study
but not in the present. Some of the patients classified as
asthma in the US study would probably have been classi-
fied as COPD in our study, since asthma medication often
is used by COPD patients. Thus, our findings do not
exclude the possibility, that certain subgroups of asthma
patients, such as patients with insufficient supportive
treatment and contributing medical and socioeconomic
factors run an increased risk to develop IPD. However,
our conclusion is that asthma without COPD is not an in-
dependent risk factor for IPD in a population with good
availability of medical care.
A strength of the retrospective method used is that it
gave a close to 100 % coverage of all consecutive IPD
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patients in the area during 13 years. The success of this
design relies on the quality of data in the medical records.
In Sweden, medical records usually contain very detailed
information on manifestations, underlying diseases and
outcome. A weakness is that vaccination status only was
mentioned in a minority of medical records. Furthermore,
there is no centralized registration concerning the vaccin-
ation status of each individual, and sales statistics of vac-
cines are not official. We are still convinced that PPV-23
was largely underused in Sweden, as shown in a study from
another part of the country [43]. Another weakness is that
smoking and alcohol abuse might not be mentioned, so
the impact of these factors may be underestimated. The
impact of celiac disease, which has been shown to predis-
pose for IPD [43], is also probably underestimated, since it
is often not mentioned even when it is known.
The high incidence and mortality among elderly and in
certain risk groups make vaccination a high priority, pro-
vided immunogenicity can be shown in these groups. Vac-
cination of infants, is probably also of benefit to risk
groups, because the conjugated vaccines decrease carriage
in infants and young children thereby protecting the elderly
and risk groups through herd immunity. Continuous sur-
veillance of serotype distribution among IPD cases is neces-
sary to be able to estimate the potential benefits of
vaccination of risk groups, since herd immunity may lead
to an increased proportion of IPD caused by non-vaccine
types [44, 45]. Hopefully, new PCVs protecting against
more serotypes, or even pneumococcal vaccines providing
serotype independent protection will be developed in fu-
ture, in order to further reduce the high burden of disease
caused by IPD.
Conclusion
This study, together with two earlier studies, per-
formed in the same area using the same protocol,
gives a unique insight in how pneumococcal epidemi-
ology has developed without impact of vaccination
during 45 years. These findings may also be valid for
other countries at a comparable socioeconomic level.
The study creates the baseline needed for a future
evaluation of PCV in the general childhood vaccin-
ation program, because detailed information on mani-
festations, death, severity, complications and risk
groups is needed to be able to fully understand the
effects of vaccination. This study provides important
baseline data which have to inform immunization
policy.
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